Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Oxford Lane Capital Corp trades at $9.16 (market cap $891.54M). The key difference: Amphastar Pharmaceuticals Inc and Oxford Lane Capital Corp are close in size by market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OXLC | |
|---|---|---|
Market Cap | $826.08M | $891.54M |
Sector | Health | Financials |
52-Week High | $30.81 | $20.80 |
52-Week Low | $16.87 | $8.15 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
OXLC trades at $9.13, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI readings. The company reported a net income margin exceeding 100% for 2025, yet recent quarterly earnings have consistently missed expectations, including a significant loss in Q1 2026. Dividend payments remain active, but negative ROE and ROA highlight financial strain. Analyst sentiment is divided, with a 50% buy rating amid concerns over net asset value declines and high distribution yields.
The outlook for OXLC is clouded by severe profitability challenges and volatile earnings, presenting high risk. While the dividend yield attracts income seekers, sustained NAV erosion and operational cash outflows signal underlying weakness. Investment opportunity hinges on a turnaround in CLO equity markets, but current fundamentals suggest caution is warranted for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
